INVEGA TRINZA DIN 02455943
Status: Marketed
Holder: JANSSEN INC
Molecule: PALIPERIDONE (PALIPERIDONE PALMITATE)
Available to quote
Health Canada record
| Active ingredient(s) | PALIPERIDONE (PALIPERIDONE PALMITATE) 175 MG |
|---|---|
| Dosage form | Suspension (Extended-Release) |
| Route | Intramuscular |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N05AX13 PALIPERIDONE |
| Original market date | 25-Jul-2016 |
| Current status date | 25-Jul-2016 |
| Source | Health Canada DPD |
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PALIPERIDONE (PALIPERIDONE PALMITATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02354241 | INVEGA SUSTENNA | JANSSEN INC | Suspension (Extended-Release) | PALIPERIDONE (PALIPERIDONE PALMITATE) 150 MG | Marketed |
| 02354217 | INVEGA SUSTENNA | JANSSEN INC | Suspension (Extended-Release) | PALIPERIDONE (PALIPERIDONE PALMITATE) 50 MG | Marketed |
| 02354225 | INVEGA SUSTENNA | JANSSEN INC | Suspension (Extended-Release) | PALIPERIDONE (PALIPERIDONE PALMITATE) 75 MG | Marketed |
| 02354233 | INVEGA SUSTENNA | JANSSEN INC | Suspension (Extended-Release) | PALIPERIDONE (PALIPERIDONE PALMITATE) 100 MG | Marketed |
| 02456001 | INVEGA TRINZA | JANSSEN INC | Suspension (Extended-Release) | PALIPERIDONE (PALIPERIDONE PALMITATE) 525 MG | Marketed |
| 02455986 | INVEGA TRINZA | JANSSEN INC | Suspension (Extended-Release) | PALIPERIDONE (PALIPERIDONE PALMITATE) 263 MG | Marketed |
| 02455994 | INVEGA TRINZA | JANSSEN INC | Suspension (Extended-Release) | PALIPERIDONE (PALIPERIDONE PALMITATE) 350 MG | Marketed |
| 02354209 | INVEGA SUSTENNA | JANSSEN INC | Suspension (Extended-Release) | PALIPERIDONE (PALIPERIDONE PALMITATE) 25 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 18360 | 2016-06-23 | Supplement to a New Drug Submission (SNDS) | NEW FORMULATION AND NEW STRENGTHS |